SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
September 30, 2013
Date of Report
(Date of Earliest Event Reported)
SOLIS PHARMA US, INC.
(Exact Name of Registrant as Specified in its Charter)
TREEGATE ACQUISITION CORPORATION
(Former Name of Registrant as Specified in its Charter)
Delaware 000-54832 46-1873961
(State or other (Commission File Number) (IRS Employer
jurisdiction Identification No.)
of incorporation)
Solis Pharma U.S., Inc.
2209 Lake Vilma Drive
Orlando, Florida 32835
(Address of Principal Executive Offices)
215 Apolena Avenue
Newport Beach, California 92662
(Former Address of Principal Executive Offices)
202-387-5400
(Registrant's Telephone Number)
ITEM 3.02 Unregistered Sales of Equity Securities
On October 1, 2013, Solis Pharma US, Inc. (formerly Treegate
Acquisition Corporation) (the "Registrant" or the "Company") issued
13,000,000 shares of common stock pursuant to Section 4(2) of the
Securities Act of 1933 at par representing 97% of the total
outstanding 13,400,000 shares of common stock.
ITEM 5.01 Changes in Control of Registrant
On September 30, 2013, the following events occurred which resulted
in a change of control of the Registrant:
1. The Registrant redeemed an aggregate of 19,600,000 of the then
20,000,000 shares of outstanding stock at a redemption price of $.0001
per share for an aggregate redemption price of $1,960.
2. The then current officers and directors resigned.
3. New officer(s) and director(s) were appointed and elected.
The disclosure required by Item 5.01(a)(8) of Form 8-K was previously
filed with the Securities and Exchange Commission on Form 10-12G filed on
October 10, 2012 as supplemented by the information contained in this
report.
The Registrant intends to develop and supply premium quality over-the-
counter medications and nutritional supplements emphasizing high value and
premium quality with advanced technology and delivery systems.
ITEM 5.02 Departure of Directors or Principal Officers;
Election of Directors
On September 30, 2013, James M. Cassidy resigned as the Registrant's
president, secretary and director.
On September 30, 2013, James McKillop resigned as the Registrant's vice
president and director.
On September 30, 2013, Diego Leiva and Dr. George Restea were named as
the directors of the Registrant.
On September 30, 2013, Diego Leiva was appointed Chief Executive Officer
and President of the Registrant.
Diego Leiva has extensive experience in start-up and turnaround
and high-growth organizations with over 40 years experience in
telecommunications, technology and services organizations in the United
States and internationally. From 2000 to the present, Mr. Leiva has served
as the president of US Financial Services, LLC, Miami, Florida providing
consulting services to companies and wealthy individuals in several
specialized areas: negotiation, including the international sale of medium
term bank notes and bank guarantees; negotiation and settlement of commercial
and residential insurance claims; and directed staff augmentation and
recruitment of candidates for classified IT positions for vendors providing
contract work to the U.S. government. From 2009 to 2012 (as chief executive
officer from 2011 to 2012), Mr. Leiva worked with Banah International Group,
Miami, Florida which imports bulk and packaged cane sugar produced in Latin
America and managed the complete transaction process including contract
negotiations, purchase/sales, logistic requirements, letters of credit,
budget and business plan preparation and implementation with the development
of a national branding and distribution strategy to market cane sugar
packaged products through major retailers focusing on institutional and
industrial sector in the United States.
George Restea, MD, received his medical degree from the Institute of
Medicine and Pharmacy University of Bucharest in 1979 and performed his
medical residency in Internal Medicine from 1981 through 1983 at the
University of Illinois Hospital and from 1983 to 1984 at the Louisiana
State University Long Memorial Hospital. Dr. Restea is certified by the
American Board of Internal Medicine and is board eligible in sleep medicine.
He is a member of the American Medical Association, Florida Medical Society
and a member of the American Academy of Sleep Medicine. Since 1988, Dr.
Restea has been with the Bradford Hospital Inc., Starke, Florida as Medical
Director of The Respiratory Therapy Department (1988 to present), Chief of
Staff (1995 to 1996), Medical Director in the Starke Sleep Laboratory (1996
to 2005), Medical Director at the Sleep Medicine Center (2005 to present)
and Chairman of the Medicine-Surgery Committee at the Bradford Hospital
Shands Starke Regional Medical Center (2005 to present).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunder duly authorized.
SOLIS PHARMA INC.
Date: October 1, 2013 /s/ Diego Leiva
President
